Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
The role of SBRT as an ablative treatment in oligometastatic patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Debén Méndez Beatriz, Rodríguez Roldán Marta, Garrido Botella Maria Isabel, González Cantero Mercedes, Teja Ubach Macarena, La Rosa Alonso, Rosel Aller Rafael, Belinchón Olmeda Belén, Miralles Olivar Lara, Enriquez Luis Alberto Glaría, De Manso De Lema Aurea, Duque Santana Victor, Díez Sebastián Jesús, Gonzalez Del Portillo Elisabet
Аннотация
BACKGROUND: Extracranial oligometastatic disease, defined as up to five metastases, represents an intermediate cancer state with potential for long-term control. Stereotactic body radiotherapy (SBRT) is a non-invasive treatment associated with high local control, limited toxicity, and the ability to delay systemic therapy. This study reports institutional outcomes of SBRT across oligometastatic scenarios.
MATERIALS AND METHODS: We retrospectively analyzed 259 patients with 401 extracranial oligometastatic lesions from solid tumors treated with SBRT between 2016 and 2022. Patients were classified according to the ESTRO-EORTC consensus as oligorecurrence, oligoprogression, or oligopersistence, and as synchronous or metachronous. The eligibility criteria included ECOG 0-1, life expectancy > 6 months, ≤ 5 treatment-naïve extracranial metastases, and no intracranial disease. Survival outcomes were estimated using the Kaplan-Meier method.
RESULTS: After a median follow-up of 68.7 months, SBRT achieved durable local control exceeding 80% beyond 4 years across all metastatic sites, with lung and lymph node lesions showing the best outcomes. Overall disease control declined due to new metastases; however, over 40% of lesions remained progression-free at 6 years. Superior outcomes were observed in patients with genuine oligometastatic disease, de novo or synchronous presentation, and fewer treated lesions. Median overall survival (OS) was 93.8 months (95%CI 81.1-106.4) and was longer in patients with initially locoregional disease and prostate cancer.
CONCLUSIONS: In this retrospective single-center experience, SBRT achieved durable local control with acceptable toxicity in selected patients with extracranial oligometastatic disease. These findings are consistent with previously published series and support the role of SBRT as a metastasis-directed approach in carefully selected patients. Prospective studies are needed to better define prognostic subgroups and optimize patient selection.
MATERIALS AND METHODS: We retrospectively analyzed 259 patients with 401 extracranial oligometastatic lesions from solid tumors treated with SBRT between 2016 and 2022. Patients were classified according to the ESTRO-EORTC consensus as oligorecurrence, oligoprogression, or oligopersistence, and as synchronous or metachronous. The eligibility criteria included ECOG 0-1, life expectancy > 6 months, ≤ 5 treatment-naïve extracranial metastases, and no intracranial disease. Survival outcomes were estimated using the Kaplan-Meier method.
RESULTS: After a median follow-up of 68.7 months, SBRT achieved durable local control exceeding 80% beyond 4 years across all metastatic sites, with lung and lymph node lesions showing the best outcomes. Overall disease control declined due to new metastases; however, over 40% of lesions remained progression-free at 6 years. Superior outcomes were observed in patients with genuine oligometastatic disease, de novo or synchronous presentation, and fewer treated lesions. Median overall survival (OS) was 93.8 months (95%CI 81.1-106.4) and was longer in patients with initially locoregional disease and prostate cancer.
CONCLUSIONS: In this retrospective single-center experience, SBRT achieved durable local control with acceptable toxicity in selected patients with extracranial oligometastatic disease. These findings are consistent with previously published series and support the role of SBRT as a metastasis-directed approach in carefully selected patients. Prospective studies are needed to better define prognostic subgroups and optimize patient selection.